⌘K
Loading ticker…
Mineralys Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Mineralys Therapeutics, Inc. Common Stock (MLYS) has a 3-month relative strength percentile of 62 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 52. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.6%, relative volume 2.40×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
62 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
No attention data for this ticker yet — it joins the daily scan once a baseline builds.
MLYS is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $48M notional. Top 3 carry $128M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $48M |
| XBIState Street SPDR S&P Biotech ETF | 0.65% | $48M |
| IWMiShares Russell 2000 ETF | 0.04% | $32M |
| VXFVanguard Extended Market ETF | 0.02% | $17M |
| IWOiShares Russell 2000 Growth ETF | 0.09% | $11M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MLYS Jan avg: -1.45% median: -14.88% win: 33% σ: 24.53% n: 3 2023-02-13 → 2026-05-29 | MLYS Feb avg: 5.21% median: -4.43% win: 25% σ: 24.07% n: 4 2023-02-13 → 2026-05-29 | MLYS Mar avg: 9.59% median: -9.67% win: 25% σ: 42.92% n: 4 2023-02-13 → 2026-05-29 | MLYS Apr avg: -7.84% median: -7.81% win: 0% σ: 5.56% n: 4 2023-02-13 → 2026-05-29 | MLYS May avg: 10.05% median: 8.87% win: 100% σ: 5.89% n: 4 2023-02-13 → 2026-05-29 | MLYS Jun avg: -1.43% median: -8.38% win: 33% σ: 16.36% n: 3 2023-02-13 → 2026-05-29 (current) | MLYS Jul avg: -2.21% median: 4.58% win: 67% σ: 12.93% n: 3 2023-02-13 → 2026-05-29 | MLYS Aug avg: 0.14% median: 0.16% win: 67% σ: 9.26% n: 3 2023-02-13 → 2026-05-29 | MLYS Sep avg: 38.87% median: -2.42% win: 33% σ: 92.63% n: 3 2023-02-13 → 2026-05-29 | MLYS Oct avg: -0.16% median: 7.75% win: 67% σ: 16.13% n: 3 2023-02-13 → 2026-05-29 | MLYS Nov avg: -4.29% median: -4.56% win: 33% σ: 9.69% n: 3 2023-02-13 → 2026-05-29 | MLYS Dec avg: 3.23% median: -3.60% win: 33% σ: 23.25% n: 3 2023-02-13 → 2026-05-29 |